BRCA1 and pachyonychia congenita: Remarkably, descriptions regarding family history are different between the two expert recommendations, and the later CAPS statements list MMR genes instead of BRCA1. There are no established protocols for screening modalities, follow-up duration, or time of screening initiation/termination, though Canto proposed a surveillance program by endoscopic ultrasound (EUS) and MRI at 1–3 year intervals from age 40 or from 10 years before the earliest age of PC onset in the family [75].